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Abstract
Treatment and management of kidney disease currently presents an enormous global burden, and 
the application of nanotechnology principles to renal disease therapy, although still at an early 
stage, has profound transformative potential. The increasing translation of nanomedicines to the 
clinic, alongside research efforts in tissue regeneration and organ-on-a-chip investigations, are 
likely to provide novel solutions to treat kidney diseases. Our understanding of renal anatomy and 
of how the biological and physicochemical properties of nanomedicines (the combination of a 
nanocarrier and a drug) influence their interactions with renal tissues has improved dramatically. 
Tailoring of nanomedicines in terms of kidney retention and binding to key membranes and cell 
populations associated with renal diseases is now possible and greatly enhances their localization, 
tolerability, and efficacy. This Review outlines nanomedicine characteristics central to improved 
targeting of renal cells and highlights the prospects, challenges, and opportunities of 
nanotechnology-mediated therapies for renal diseases.
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Nanotechnology involves the engineering of atoms and molecules at the submicron scale. 
The unique optical, electrical, physical, and chemical properties of matter at this scale can 
yield materials that behave differently from their macroscale counterparts. Inorganic or 
organic multifunctional nanocarriers, which we refer to as nanoparticles (NPs), can be 
engineered to deliver drugs or imaging agents with unique characteristics. For example, NP 
delivery improves pharmacokinetics and biodistribution and enables targeted delivery of 
drugs to specific tissues, cells, or subcellular compartments. Additionally, achieving 
spatiotemporal, triggered, and controlled release of a variety of payloads (such as small-
molecule drugs, contrast agents, peptides, proteins, deoxy and ribonucleic acids, and their 
combinations) over extended periods might be possible. Nanomedicines are typically 
degradable, biodegradable, and bioeliminable structures generally <150 nm in size that can 
incorporate the aforementioned payloads1–5. Physicochemical properties of nanomedicines 
such as composition, size, geometry and/or shape, surface charge, surface chemistry 
(including targeting ligands), hydrophobicity, roughness, rigidity, and elasticity influence 
their uptake and/or ability to target particular organs and cells6–13 (FIG. 1).
In the 1970s, colloid-based drug delivery agents designed to improve drug therapeutic 
efficacy and reduce toxicity were termed NPs14. The term ‘nanoparticle’ is mentioned in 
over 135,000 publications, and the number of publications on this topic has doubled every 
other year between 2000 and 2014 (PubMed). Though this rapid growth seems to be 
slowing, the absolute number of articles published on the topic remains impressive at 
~15,000 per year. Monoclonal antibodies took decades to gain significant momentum; 
similarly, the broad impact of nanotechnology-based therapeutics will become more 
apparent as these technologies mature15. Exciting developments in NP design, such as the 
generation of building blocks that release drugs in response to stimuli from the disease 
environment (such as increased enzymatic activity, the presence of reactive oxygen species 
or lowered pH) or to externally delivered stimuli (such as heat or ultrasound), are laying the 
foundations for ‘prompted’ and ‘modular’ drug delivery16–23. Additionally, the ability to co-
deliver synergistic therapeutics will further enlarge the arsenal of nanomedicines for the 
treatment of a variety of diseases and facilitate important combination therapies24,25.
Nanomedicine-based genetic therapies directed to the liver, an organ that filters significant 
volumes of blood, have now been successfully developed26,27. Such established design 
principles can also be used to create NPs that can bind to, be taken up by and retained by 
diseased renal cells. Numerous in vivo NP studies initially designed to target tumours have 
resulted in serendipitous discoveries of principles underlying kidney targeting and selective 
accumulation. Such findings raised important ‘structure–activity’ correlations, which can be 
used to influence NP retention and clearance from the general circulation within kidneys, 
and these insights could be applied to overcome challenges in the generation of kidney 
targeted nanomedicines.
In this Review, we discuss the application of nanotechnology to diseases of the kidney. We 
introduce fundamental concepts of nanomedicine, examine renal anatomy and selective 
permeability in health and disease, and highlight nanotechnology research aimed at targeting 
the major renal membranes and cell types involved in disease. Furthermore, we discuss 
microfluidic- based kidney models and artificial organ-on-a-chip approaches to investigate 
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synthesis, screening and testing of NPs for renal disease therapy. Finally, we examine 
challenges in the translation of nanomedicines to the clinic.
Nanomedicines
Structure
Depending on the method of preparation or the chemical nature of the building blocks used, 
NPs can have either a solid or hollow aqueous core (FIG. 1a). Their surface layer can be 
coated with inert polymers that can shield the NP from blood components. To date, 
polyethers such as polyethylene glycol (PEG) have been mostly used for this purpose. A 
variety of payloads can be incorporated within the core or surface layers of the NPs: 
hydrophilic or hydrophobic small-molecule drugs, proteins, peptides, nucleic acids, or 
imaging agents. The surface of the NPs can be functionalized with ligands targeted to 
specific receptors or proteins of interest to achieve ‘active targeting’. Targeting ligands can 
be antibodies, antibody fragments, antibody mimetics, proteins, peptides, nucleic acids (such 
as aptamers) and small-molecule ligands (FIG. 1b). Physical characteristics such as NP size 
can also be used to achieve ‘passive targeting’ and enhanced accumulation in tumours (FIG. 
1b). Liposomes were the first nanomedicines to enter the clinic and be marketed, and 
therefore represent a large portion of clinical- stage nanomedicines. They were followed by 
polymer–drug conjugates, polymeric micelles, polymeric NPs, protein-based NPs and 
dendrimers (TABLE 1)15,28.
Current therapeutic uses
The majority of nanomedicines generated so far have been developed for cancer therapy, as 
compromised endothelial barriers in tumours facilitate NP retention (discussed below). Over 
a dozen NP platforms based on liposomes29–45, albumin46–51, polymeric micelles52–58, and 
nanosized polymer-drug conjugates59–62 have been approved by the FDA (TABLE 1). A few 
targeted NPs including Her2 scFv-targeted liposomes (MM-302)63, the first targeted 
controlled-release polymeric NP BIND-014 (REF. 64), and the first targeted short interfering 
(si)RNA NP CALAA-01 (REF. 65) are currently being tested in clinical trials for cancer 
therapy. Although many nanomedicines improve the pharmacokinetics and biodistribution of 
drugs, so far, only one nanomedicine, CPX351, has increased survival in patients with 
cancer when directly compared with the conventional parent drug66. These findings 
underscore the need to rethink strategies for the development of NPs, including potential 
patient selection to identify those most likely to respond to nanomedicines.
Nanotechnology-enabled diagnostic and therapeutics based on dendrimers67–69, gold70–72, 
silica73–75, iron oxide71,76,77 and hafnium oxide78,79 are also currently under clinical 
investigation, with the majority intended for oncological applications (TABLE 1). For 
example gold NPs decorated with a surface of PEG conjugated to TNFα molecules are in 
phase I/II trials for solid tumour therapy80. Silica NPs in combination with gold are being 
tested in thermal ablation therapy of head and neck cancers81. Two MRI contrast agent iron-
oxide NPs (Ferumoxtran-10® and Ferumoxytol®) are in clinical trials for cancer 
imaging82,83. A therapeutic version of iron oxide NPs termed NanoTherm® was approved in 
Europe in 2010 for the thermal ablation of glioblastomas (magnetic hyperthermia 
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treatment)84. Clinical trials have begun for the investigation of hafnium oxide NPs (phase I), 
which will be used as radiosensitizers in patients with soft-tissue sarcomas78. 
Nanomedicines are also undergoing clinical translation for gene therapy85, RNA 
interference26,65,86–88, and immunotherapy89,90. Viral NPs have found utility in the delivery 
of a range of therapeutics and have been clinically validated for gene therapy 
applications91,92,93. For example, the tumour-homing oncolytic pox virus was engineered to 
generate JX-594, a particle that expresses granulocyte colony-stimulating factor (G-CSF) to 
potentially increase the immunological antitumour response94. Exosomes are being explored 
as targeted vectors in drug delivery, where their signalling properties can be exploited to 
manipulate cellular proteomic functions beyond their current applications in kidney disease 
biomarker discovery95–98. Other novel nanomaterials including nanodiamonds99–101 and 
nanographene102,103 are receiving attention in drug- delivery applications: the adsorption of 
hydrophobic drugs to these surfaces facilitates the delivery of poorly soluble therapeutics in 
high concentrations.
Developments in nanomedicine have facilitated investigations into the delivery of multiple 
synergistic active pharmaceutical ingredients25,104,105. For example, the liposomal 
formulation of cytarabine and dauno-rubicin CPX-351 is under development for high-risk 
acute myeloid leukemia66. Design advances have also produced nanomedicines that can 
simultaneously deliver diagnostic and therapeutic agents, termed theranostics106. For 
example, liposomes containing an MRI contrast agent and an anticancer siRNA payload can 
be used to dynamically monitor and cause tumour regression107. Nanotheranostic agents that 
use near infrared absorbing agents to convert optical energy into heat for ablating tumour 
cells have also been developed and are used for image-guided photothermal therapy with 
inorganic NPs to treat tumour metastases108–110.
The versatility of NPs (antigens, adjuvants and targeting moieties can be incorporated into 
single NPs) has also led to their utilization as synthetic vaccines111,112. NPs can accumulate 
in lymph nodes, target antigen- presenting cells, and co-deliver antigens and/or adjuvants 
that can trigger impressive cellular and/or humoral responses111–117. The co-delivery of an 
antigen with a TLR7, TLR8 or TLR9 agonist in polymeric NPs strongly increased humoral 
and cellular immune responses with minimal systemic production of inflammatory cytokines 
in mice111,112. This strategy enables the use of TLR agonists as vaccine adjuvants for 
indications where cellular immunity or a robust humoral response is required.
To date, the vast majority of renal drug delivery studies have mostly investigated the 
applications of nanosized polymer–drug conjugates, liposomes118–131, or inorganic 
nanodiagnostic compounds to study renal toxicity132–140. Although organ biodistribution 
profiles of numerous NPs have been evaluated for other indications than renal diseases (such 
as tumour therapy), they are quite informative regarding NP structure–activity relationships 
(concerning NP size and charge) in the kidneys. In glomerular nephropathies, NPs 
accumulate in the glomeruli, perhaps due to increased vascular permeability and 
inflammation127,130,141,142. Despite these findings, the kidney has largely been overlooked 
as a target organ for NP-mediated drug delivery. Few systematic studies of NP glomerular 
deposition in various kidney diseases and disease stages have been conducted with 
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nanomedicines; however, the ‘tuneable’ properties of NPs and their inherent tendency for 
glomerular deposition might be exploited for the treatment of kidney diseases.
NPs and systemic circulation
Nanomedicines are currently typically administered via intravenous injection, although 
research on their oral delivery is under way (with the promise of greater patient 
compliance)143–147. The biological and physicochemical properties of NPs (FIG. 1b) 
influence their interactions with biological surroundings and affect their in vivo circulation 
and biodistribution148,149.
The protein corona
Blood contains ~3,700 distinct proteins, and a few tens of them can adsorb to NP surfaces, 
forming a ‘protein corona’ (REFS 10,150–156). Adsorption of some plasma proteins (such 
as immunoglobulins, complement proteins, and fibrinogen) can facilitate clearance by the 
mononuclear phagocyte system157 and limit NP circulation; conversely, binding of 
dysopsonin proteins (such as apolipoproteins and albumin) might prolong NP presence in 
the systemic circulation154–156. Thus, the impetus towards understanding NP interactions 
with their surroundings in vivo is strong as the protein corona can bestow a new biological 
identity to NPs158,159.
Surface modifications
To increase NP circulation time, PEGylation of the NP surface to minimize protein binding 
and render it hydrophilic has been routine practice since the mid-1970s160. Doxil, the first 
FDA-approved PEGylated ‘stealth’ liposome formulation, has a circulation half-life of up to 
~2 days45. Further investigation of the function of the protein corona, however, yielded 
contradictory results. For example, a 2016 study showed that PEGylated polystyrene NPs 
are highly prone to selective adsorption of clusterin (a 80 kDa chaperone protein), which 
reduced their nonspecific macrophage uptake in vitro161. These findings and other results 
suggest that the stealth effects of PEGylation could be mediated by changes in the nature of 
the protein corona161,162. Formation of the protein corona can also reduce the efficacy of the 
targeting ligands coupled to NPs162 or, in some instances, promote organ-specific 
accumulation, as in the case of apolipoprotein-E-mediated targeting of NPs to hepatocytes in 
vivo163. Predicting such in vivo responses will require careful analytical techniques and 
protein fingerprinting to better understand how the NP corona influences the 
pharmacokinetics, biodistribution, intrarenal biodistribution, and therapeutic efficacy of 
NPs164–167. In addition, a few animal and human studies have shown potential PEG 
immunogenicity (presence of anti-PEG antibodies) leading to rapid clearance of PEGylated 
NPs after repeated administrations168–171. The majority of these studies are based on 
liposomal NPs and further studies are needed to ascertain the exact immunogenic 
mechanisms associated with PEGylated NPs.
Pharmacokinetics
Numerous studies in tumour therapy show that NPs can enhance drug delivery, and improve 
drug Cmax, pharmacokinetics and plasma area under the curve (AUC; a measure of total 
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drug exposure over time), compared to the standard dose and formulation172–175. Hence, NP 
versus drug pharmacokinetics; encapsulated versus free circulating drugs; drug versus NP 
Cmax; drug versus NP AUC; and parameters that can further affect plasma versus kidney 
pharmacokinetics and AUC are important factors to consider for the development of 
effective nanomedicines for the kidney. The infusion time of drugs that are administered 
intravenously can vary and drugs usually reach their plasma Cmax during the period of 
infusion, after which the concentration of the drug diminishes176,177. With NP-encapsulated 
drugs, the plasma concentration of the released drug is initially low and increases 
progressively to reach its Cmax at a slower rate than that of the conventional drug64. Of note, 
the Cmax after drug release from NPs rarely reaches the levels achieved with intravenous 
injection of the free drug. This kinetic is a major advantage of nanomedicines, as it could 
reduce drug-associated toxicity, which depends on Cmax64. The free drug and the NP-
released drug have similar plasma AUCs, although that of the released drug is generally 
broad and flat, whereas that of the free drug peaks and has a tail64. These findings imply that 
NPs might reduce Cmax-associated toxicity, but not AUC-related toxicity, as the total dose of 
the drug is still released by NPs, albeit at a reduced rate.
Renal anatomy and selective permeability
The adult human kidney can contain 1–2.5 million nephrons, which maintain fluid 
homeostasis, osmoregulation, and waste filtration178. A single nephron consists of two 
filtration units: the glomerulus and a hairpin-shaped tubule composed of a proximal tubule, 
the loop of Henle, a distal tubule, and collecting duct179. The glomerulus comprises 
glomerular endothelial cells (GECs)180, a glomerular basement membrane (GBM)181, 
podocytes182, mesangial cells183, and parietal epithelial cells184 (FIG. 2).
Three distinct glomerular filtration barriers separate the vasculature from the urinary spaces 
and selectively filter blood molecules and ions, yielding a primary urinary filtrate: GECs, the 
GBM and podocytes179. In the nephrons, the renal tubules and collecting ducts concentrate 
and balance the urinary filtrate via resorption and secretion of ions, water and certain 
nutrients through channels and transporters185. Under normal conditions, blood filtration by 
size and charge by the glomerular barrier ensures that only water and small solutes (urea, 
glucose, amino acids, and mineral ions) from the plasma cross to the urine179. High 
molecular-weight plasma components, such as erythrocytes, and negatively charged 
components, such as albumin, are retained in the blood179. Electrostatic repulsion is thus a 
predominant filtration parameter, as the glomerular filtration barrier strongly favours the 
passage of anionic molecules, as shown by the glomerular permeability to larger neutrally 
charged dextran polymers186. The impairment of this barrier leads to proteinuria, a hallmark 
of glomerular diseases187.
To escape the general circulation, a NP must cross the glomerular filtration barrier (FIG. 2). 
Structural features of the glomerular barrier in the setting of renal disease, in particular 
enlarged endothelial gaps (detailed below), can be exploited for NP delivery to various 
kidney cells and components.
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NP size
NP size has been widely explored to design effective nanomedicines. Most therapeutic NPs 
are 30–150 nm and are not subject to kidney filtration into the urine, unless they are 
degraded into particles <10 nm, or the glomerular filtration barrier is damaged by disease 
(FIG. 2).
In healthy states, colloids and particles with a hydrodynamic diameter up to 5–7 nm fall 
below the kidney filtration threshold, pass through the glomerulus and are excreted188. NPs 
below 5.5 nm can be excreted via renal clearance, with an efficiency of >50% of the injected 
dose 4 h after administration188,189. Of note, some deviations from this threshold have been 
observed for 12–16 nm inorganic NPs, suggesting that case-by-case investigation of the 
renal clearance of small-sized NPs is important, as each type of NP has a distinct chemical 
composition and size-distribution profile133.
Kidney accumulation studies based on size have shown that NP accumulation is restricted to 
the glomerular mesangium (driven by mesangial cell uptake) and the kidney extracellular 
matrix, with maximal glomerular deposition for ~80 nm NPs190. One caveat of these studies 
is that most have been conducted in healthy animals, in which the renal filtration barriers are 
intact. Considering the influence of NP size on the biodistribution and clearance of 
nanomedicines, and on size-dependent renal transport, is therefore a crucial parameter for 
renal nanomedicines.
NP shape
The transport of NPs in the circulation is influenced to a greater degree by the applied 
convective forces in blood than by Brownian motion. Therefore, shape has an important 
effect on in vivo performance and biodistribution of NPs, which exist in a wide range of 
geometries191. For example, a top-down fabrication method termed particle replication in 
non-wetting templates (PRINT) utilizes lithography techniques to create polymeric NPs of a 
wide variety of geometries, shapes, and aspect ratios192,193. Cylindrical and discoidal shapes 
are uniquely subject to blood flow (they have high aspect ratios and minimal regions of 
curvature), which affects their interaction with macrophages and cell membranes as particles 
with reduced curvature undergo faster internalization upon incubation with 
macrophages194,195. Similarly, nanoworm or nanorod (elongated cylindrical) structures show 
greater tumour accumulation than other shapes196,197. Non-spherical NPs marginate to 
vessel walls more efficiently than spherical NPs, although they are also more rapidly cleared 
depending on their aspect ratio and dimension195,198,199. In general, shapes that can 
accommodate cellular membrane wrapping processes are optimal for cellular 
internalization200,201.
Interestingly, the kidney can also filter rigid NPs with high aspect ratios but with diameters 
smaller than the kidney filtration threshold, such as single-walled carbon nanotubes 
(SWCNTs) with a rod length of 100–1000 nm and diameter of 0.8–1.2 nm199. Even though 
SWCNTs have higher molecular weights (300–500 kDa) than plasma proteins (30–50 kDa), 
they are cleared by the kidney, suggesting that aspect ratio influences directional 
diffusion199. Similar NPs successfully delivered therapeutic siRNA to proximal tubule cells; 
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fibrillar carbon nanotubes delivered two synergistic siRNA payloads targeting Mep1b and 
Trp53, which reduced the expression of key proteins involved in cisplatin-induced acute 
kidney injury202. One mechanism proposed to underlie this phenomenon is that hydrostatic 
forces orient carbon nanotubes perpendicularly to the GBM, enabling the insertion of their 
<10 nm axis. This shape might be optimal for targeting podocytes, which are difficult to 
access as they are protected by the fenestrated endothelial cells and the GBM199,203 (FIG. 
2).
NP charge
Highly positively charged NPs are rapidly cleared from the circulation by cells of the 
mononuclear phagocyte system owing to increased protein binding or high affinity 
interactions with phagocytic cells6,204. Negatively charged NPs can also be more subject to 
selective cellular uptake (by macrophages, for example) than NPs with neutral surfaces205. 
NPs with a surface charge of <15 mV had minimal macrophage uptake and long circulation 
times206. Anionic NPs (surface charge of −10.6 mV) had lower levels of liver and spleen 
accumulation than near-neutral polymeric micelles (1.3mV)207. Cationically charged NPs 
undergo high non-specific uptake in a variety of cells (cancer cells and macrophages), and 
can also achieve endosomal release194. This property is particularly important for the 
effective delivery of payloads for RNA interference (RNAi), which requires cytosolic 
delivery for efficacy10,208–210.
Considerations regarding NP charge should also include the charge contribution of targeting 
ligands that are grafted on NP surfaces for retention in target tissue and/or receptor-mediated 
endocytosis, leading to increased intracellular drug concentrations1,12,15,211 (FIG. 1). Charge 
selectivity is also an important criterion for kidney filtration. The suborgan distribution of 
intravenously administered ultrasmall anionic NPs (3.7 nm quantum dots) at the level of 
kidney cells was investigated using fluorescence imaging212. The majority of NPs were 
initially distributed within the peritubular capillaries or the glomerular arterioles, passed 
through the fenestrated glomerular endothelium, and were gradually taken up by the 
mesangial cells for up to 30 days212. Interestingly, only trace amounts of quantum dots could 
be detected in the urine. As the negative charge of the glomerular basement membrane 
prevents the filtration of anionic quantum dots, cationically charged quantum dots of similar 
size were found in much higher concentrations in the urine212. These studies provide a 
framework for understanding charge principles across kidney filtration barriers, which are 
predominantly negatively charged, in particular as applied to the ultrasmall inorganic NPs 
often used in imaging applications.
Targeting renal cells
The glomerular endothelial cell barrier
Blood capillaries in the kidneys are lined with GECs, which form the first part of the 
glomerular filtration barrier. They are characterized by fenestrations and transcellular holes 
(60–80 nm) filled with an endothelial glycocalyx. The glycocalyx (composed of 
podocalyxin, sialoglycoprotein, and podoplanin)123 is a polysaccharide-rich >400 nm layer 
present on 30–40% of GEC surfaces180,213. This layer mechanically limits the access of 
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circulating plasma components to endothelial cell membranes via a filamentous structure 
and strong negative charge214. The proteoglycan structure effectively makes the fenestrae 
narrow and restrictive, preventing passage of albumin from plasma, but facilitating water 
permeability215.
The GECs and endothelial surface layer are important components of the glomerular 
filtration barrier. Impairment of the endothelial surface layer leads to albuminuria and 
vascular disease123, and damage to this layer can lead to scarring and glomerulosclerosis123. 
Preclinical and clinical studies have shown that damage to the endothelial surface layer 
strongly correlates with diabetes-mellitus-induced proteinuria216,217.
Lipidoid siRNA NPs effectively silenced multiple endothelial genes in the heart, lung, and 
kidney in vivo with minimal effects on gene expression in hepatocytes or immune cells218. 
Similar strategies can be used to deliver specific antisense219,220, siRNA26,65,86,87, mRNA88, 
or DNA inhibitor oligonucleotides85 to damaged GECs for repair and restoration of 
function. In a mouse model of glomerulonephritis, liposomes coated with an antibody 
directed against E-selectin, which is specifically expressed on activated endothelial cells 
during inflammation, were used to successfully deliver dexamethasone to CD31+ GECs, 
which reduced glomerular endothelial activation and albuminuria after 7 days221. Such 
studies demonstrate the potential of using disease specific epitopes on the surface of GECs 
for targeted drug delivery. This approach is particularly beneficial as standard anti-
glomerulonephritis therapies consist of glucocorticoids and cytotoxic drugs with systemic 
adverse effects.
The glomerular basement membrane
The GBM is an anatomic barrier of connective tissue composed of collagen IV, laminin, and 
proteoglycans (mostly agrin); these proteins are secreted by the GECs and podocytes222. 
The GBM is an integral component of the glomerular filtration barrier and acts as an 
intermediary sieving matrix, but can also accumulate pro-angiogenic ligands and secreted 
factors that mediate cellular communication between podocytes and GECs. Agrin, a major 
component of the heparin sulfate proteoglycan, has a high negative charge owing to core 
proteins such as syndecan, glypican, or biglycan with sulfated glycosaminoglycan side 
chains, which contribute to the net negative charge of the GBM180,181. The charge difference 
between the GBM and the blood has been proposed to be the main reason for the repulsion 
of plasma albumin (68 kDa, ~3.6 nm, negative charge).
Scanning electron microscopy studies showed that the GBM is a highly organized non-
amorphous mesh-work of interconnected polygonal fibrils 4–10 nm thick223. In healthy 
states, the core of the GBM is more densely packed (10-nm pores) than the peripheral fibril 
network; however pores were enlarged up to 40 nm, in a rat proteinuric nephritis model223 
(FIG. 2). Subdiffraction resolution stochastic optical reconstruction microscopy (STORM) 
and STORM-electron microscopy showed that GBM-associated proteins have a highly 
oriented macromolecular organization of agrin, laminin, and collagen IV224. Mutations in 
the gene that encodes collagen IV disrupt the self-polymerized collagen network and cause 
Alport syndrome, a hereditary disease that stems from GBM dysfunction225. Mutation of the 
LAMB2 gene, which encodes laminin subunit β2, prevents the assembly of the laminin 
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complex LM-521 (a heterodimer composed of the laminin subunits β2, α5 and γ1), which 
leads to abnormal renal and neuromuscular phenotypes (Pierson syndrome), including 
splitting of the GBM226. Breakdown of the GBM in Pierson syndrome might be due to 
reduced levels of laminin trimer polymerization, a process that maintains basement 
membrane integrity181.
The design of mRNAs targeted to either podocytes or GECs, both of which synthesize the 
matrix to form and maintain the normal composition of the membrane, might be necessary 
to repair mutations of the matrix proteins. For example, NPs bearing specific peptide 
sequences that bind to collagen IV target subendothelial collagen IV in the vasculature227. 
Interestingly, during renal clearance, cyclodextrin-containing polymer-based cationic NPs 
that contain siRNAs accumulate and disassemble at the GBM, which might have broader 
repercussions for NPs that assemble via electrostatic interactions between their matrix and 
payload228. Whether this property could be exploited to target the GBM is not yet clear. 
Using targeted NPs to silence GBM protein expression in order to reverse the effects of 
mutations in the genes encoding laminin and collagen IV would be an interesting avenue to 
explore in the treatment of hereditary diseases. In addition, NPs targeted to the GBM could 
help deliver drugs, mRNAs or siRNAs to podocytes and glomerular endothelial cells, 
because both types of cells sit on the GBM.
Podocytes
Podocytes have unique features such as foot processes and the slit diaphragm, a 40 × 140 Å-
wide229 bridge, mainly composed of nephrin, that connects juxtaposed foot processes. The 
slit diaphragm is porous but prevents the passage of large macromolecules such as 
proteins230. Since the discovery of nephrin (encoded by NPHS1) and podocin (encoded by 
NPHS2) as integral components of the slit diaphragm, several other podocyte-related 
proteins, such as glycogen synthase kinase 3b, have been discovered. Mutations in these 
proteins are linked to genetic diseases of the glomerulus216.
Foot process effacement is a classical sign of podocyte injury that correlates with the onset 
of proteinuria, underscoring the importance of these cells as the final size-selective filtration 
barrier to albumin. As podocytes have limited capacity for repair or regeneration, effective 
glomerular function is highly sensitive to podocyte number and glomerular filtration surface 
area216. Podocytes are therefore highly attractive therapeutic targets to treat refractory 
congenital nephrotic syndromes (such as the Finnish type)231.
In immortalized mouse and human podocytes (AB8/13 cells), activation of TNFα led to 
increased vascular cell adhesion protein 1 (VCAM-1) expression232. Anti-VCAM-1-coated 
lipidic NPs were used to deliver the potent immunosuppressant rapamycin to these activated 
podocytes, which inhibited cell migration232. Similar synthetic lipidic systems, such as 
synthetic, amphiphilic, interactive transfection reagent (SAINT), have also been used to 
package therapeutic proteins such as the large GTPase dynamin or antibodies, and were 
taken up by podocytes and fibroblasts233. The utility of this approach remains to be 
validated in vivo.
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We have shown that polymeric NPs targeted to the neonatal Fc receptor (FcRn) effectively 
transport insulin across the intestinal barrier143,144. The FcRn signalling pathway is involved 
in the vectorial transcytosis of IgG and protects IgG and albumin from degradation234. FcRn 
is also expressed in podocytes, where it prevents IgG from clogging the glomeruli and 
controls albumin excretion234. NPs that are targeted to FcRn, are taken up via endocytosis, 
and are capable of releasing their payload from endosomes (for example via pH-sensitive 
chemistries or other ligands that can cause endosomolysis) might prove an effective means 
to deliver drugs into podocytes.
The glomerular endothelium and podocytes express several integrin receptors including 
integrin αvβ3. Activation of integrin αvβ3 induces urokinase plasminogen activator surface 
receptor signalling in podocytes, which in turn leads to foot process effacement and loss of 
urinary protein235. In diabetic nephropathy, hyperglycaemia stimulates the secretion of 
integrin αvβ3 ligands such as vitronectin by vascular cells, leading to the activation of αvβ3 
integrins235. Blocking the ligand occupancy of αvβ3 with the F(ab′)2 fragment (obtained by 
pepsin digestion of an immunoglobulin) of an antibody directed against the extracellular 
domain of the integrin β3 subunit inhibited the development of diabetic nephropathy in 
diabetic pigs and rats236,237. Using NPs targeted to integrin αvβ3 that transport siRNA 
payloads directed against inflammatory pathways in podoctyes could be a promising 
approach to treat podocyte injury in kidney disease. Inorganic NPs surface modified with a 
cyclic RGD targeting motif (a sequence originally found in fibronectin) and targeted to 
integrin αvβ3, underwent receptor-mediated uptake and accumulated in vesicle-like 
structures in 2D podocyte cultures and whole glomeruli ex vivo238. The identification of 
podocyte-specific targets, coupled with the identification of specific upregulated pathways 
that underlie podocyte function in health and disease, will enable the creation of 
nanomedicines targeted to this important cell type for clinical translation and treatment of 
glomerulopathies.
Mesangial cells
Mesangial cells function as microvascular pericytes and maintain the structural architecture 
of the glomerular capillary (FIG. 2). They are primarily responsible for glomerular matrix 
growth and homeostasis, regulation of filtration surface area, and clearance of apoptotic cells 
or immune complexes near glomerular capillaries183.
Increased matrix production by mesangial cells and glomerulosclerosis are hallmarks of 
kidney disease and mesangial cell dysfunction is a key event in diabetic nephropathy. 
Hyperglycaemia induces excess production of reactive oxygen species, growth factors, and 
cytokines in mesangial cells183. Targeted NP-mediated drug delivery to mesangial cells 
would therefore be useful to treat various kidney diseases. NPs have the potential to diffuse 
and accumulate for prolonged periods in the mesangium if they can successfully cross the 
glomerular endothelial barrier. In fact, PEGylated gold NPs (with negative surface charge 
and variable PEG lengths) can be delivered to the kidney mesangium depending on their 
size167. Intravenously injected 75 nm NPs effectively targeted the kidney mesangium, 
whereas NPs >130 nm were abundant in the liver and spleen but not detected in the kidney. 
In this study NPs of ~130 nm in diameter provided an ‘in vivo calibration’ for the size of 
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glomerular endothelial pores in physiologically relevant conditions as values for this 
threshold are usually derived from direct measurements of transmission and scanning 
electron microscopy images, for which sample preparation (repeat dehydration) might lead 
to pore shrinkage167. Cyclodextrin-containing siRNA NPs quickly accumulated in the GBM 
and also effectively delivered siRNA to mesangial cells to silence enhanced green fluoescent 
protein (EGFP) expression in the glomeruli of transgenic mice167,239.
Antibody-coated immunoliposomes effectively target mesangial cells. For example, NPs 
coated with anti-integrin-α8 monoclonal antibodies targeted mesangial cells in lupus 
glomerulonephritis in mice105. Similarly, NPs coated with OX7, an anti-Thy-1 membrane 
glycoprotein (Thy-1) monoclonal antibody, targeted the rat mesangium in mesangial 
proliferative glomerulonephritis127,131. Interestingly, the liposomes investigated in these 
studies were 130–170 nm in size, suggesting that such NPs can cross the glomerular 
basement membrane via surface ligand targeting (unlike non-targeted NPs)131. For optimal 
therapeutic effects, targeted drug delivery systems such as immunoliposomes can be used to 
deliver high intracellular concentrations of molecules that usually have severe systemic 
toxicities (glucocorticoids, cyclophosphamide, azathioprine, fatty acids, anticoagulants or 
antithrombotic agents) to mesangial cells using NPs conjugated to antibodies directed 
against antigens expressed on mesangial cells.
Tubular epithelial cells
The proximal tubules both secrete waste products and reabsorb useful nutrients into and 
from the urine122. Two barriers are involved in those processes: the capillary endothelial 
cells at the basolateral side of the proximal tubular cells and the tubulointerstitium between 
the capillaries and tubular cells122 (FIG. 2). Renal peritubular capillaries have fenestrations 
(60–70 nm wide), which are covered by a diaphragm (3–5 nm thick)122. In order to cross the 
tubulointerstitium, particles need to be smaller than the size of this diaphragm (<5 nm), and 
positively charged as the fenestrae are negatively charged owing to the presence of heparin 
sulfate122. Furthermore, the tubulointerstitium also contains fibroblasts and dendritic cells 
within an extracellular matrix consisting of proteoglycans, glycoproteins, fibrils, and 
interstitial fluid122. The tubular epithelium is highly susceptible to injury, which leads to 
tubular cell loss and sublethal proinflammatory and fibrogenic injuries240. Fibrosis is the 
downstream pathological manifestation of chronic kidney disease and is strongly correlated 
with disease progression. Hence, NPs designed to deliver drugs that prevent cell death, 
reduce renal fibrosis and inflammation, and/or promote the regeneration of tubules could be 
highly valuable241.
An optimal strategy to reduce fibrosis would be to target proximal tubular epithelial cells, as 
these cells play an important role in the pathogenesis of tubulointerstitial fibrosis. Targeted 
drug delivery strategies to inhibit pathways that are activated in disease with TGFβ kinase 
inhibitors, p38 mitogen activated protein kinase (p38 MAPK) inhibitors, Rho-associated 
kinase (ROCK) inhibitors or PDGF receptor kinase inhibitors, for example, could slow or 
even prevent progression to renal disease122.
As proximal tubule cells accumulate siRNA, several RNAi-based strategies have been 
proposed to treat acute kidney injury. NP-mediated delivery of siRNA can increase the 
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accumulation of siRNA molecules within proximal tubule cells and facilitate combination 
treatments or controlled-release modes of action242,243. As mentioned above, carbon 
nanotubes with siRNAs against Trp53, Mep1b and Ctr1 reduced renal injury, fibrosis and 
immune infiltration in a cisplatin-induced model of acute kidney injury202. Although the 
pharmacokinetic profiles of the carbon nanotubes were comparable in mice and primates, 
suggesting that this therapy might be amenable to humans, the potential advantages of 
siRNA delivery using these NPs should also be investigated in the clinic.
A 2015 report showed that 400 nm NPs localize preferentially in the kidney compared to 
other organs, and selectively accumulate in the renal proximal tubules244. This characteristic 
suggests that antifibrotic compounds could be delivered directly to proximal tubular cells, 
which would increase renal specificity and minimize adverse and non-targeted effects; 
however, further studies are required to confirm these findings.
The effective targeting and optimal transport strategies to deliver xenobiotics and various 
drug conjugates (with polymers and/or proteins) to tubular cells have been discussed at 
length elsewhere122. The role of proximal tubular cells transporters, which are involved in 
the tubular reabsorption and secretion of small molecules, in the efflux of colloidal or 
nanosized drug-delivery systems remains to be elucidated. Large macromolecular structures 
are highly unlikely to be transported into tubular cells via this mechanism in healthy states; 
the transport of NPs and large macromolecules into tubular epithelial cells in disease states 
needs to be further investigated.
Catechol-derived, low-molecular-weight chitosan NPs were developed and investigated for 
the treatment of renal fibrosis in a 2014 study120. This self-assembled nanocomplex, 
designed to selectively release its pay-load inside cellular endosomes for maximal 
specificity, was specifically absorbed in the proximal tubules in mice. Intravenous delivery 
of the active anti-fibrosis compound emodin with these NPs attenuated fibrotic progression 
in a murine model of renal obstruction. Multi-targeted kinase inhibitors, and targeted 
delivery with nanomedicines, might also achieve antifibrotic effects. For example, sunitinib 
(a multi-targeted kinase inhibitor) has been evaluated for targeted drug delivery (conjugated 
to the kidney-specific carrier lysozyme)245, indicating that lysozyme could be utilized as a 
targeting ligand. A 2015 study investigated the effects of delivering an exogenous 
microRNA (miR-146a) using polyethylen-imine NPs in a mouse model of renal fibrosis 
induced by unilateral ureteral obstruction246. These positively charged NPs markedly 
reduced renal fibrosis by inhibiting inflammation via the suppression of TGFβ1 and Smad 
mRNA expression, which are responsible for the transcription of profibrotic genes.
A 2015 study showed that 5 nm dextran-based NPs and similar-sized poly(amidoamine) 
dendrimer NPs were filtered and internalized by renal tubular epithelial cells in a dose and 
time-dependent manner137. The administration of dextran NPs increased cellular albumin 
endocytosis and megalin expression but did not affect AQP-1 expression, as measured by 
dose-dependent urinary output. Similar effects were observed with the dendrimer NPs, 
which, in addition, led to an increase in clathrin expression. No major renal detrimental 
effects of dendrimers were reported, although changes in proximal tubule endocytosis and 
Kamaly et al. Page 13
Nat Rev Nephrol. Author manuscript; available in PMC 2017 September 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
protein cellular expression levels suggest that these parameters should be monitored as 
researchers develop nanodrugs of various compositions and sizes targeted to the kidney.
Renal cell carcinoma
Renal cell carcinoma is the most lethal urologic cancer and affected patients have limited 
treatment options247. Over the past decade, cytokine-based therapies that target VEGF and 
mTORC pathways have improved the treatment of this disease; however, resistance 
mechanisms exist, which could be mitigated with combination therapies.
Numerous liposomal strategies for drug delivery in renal cell carcinoma have been 
investigated in preclinical studies, but only a few clinical studies have been carried 
out248–259. The majority of these studies administrated standard renal disease therapies and 
used antibody- targeting strategies. PEGylated-liposomal doxorubicin (Doxil) was used to 
treat patients with refractory renal cell cancer in a phase II clinical trial but had no efficacy 
and was mildly toxic257. Polymeric NPs have also been investigated in preclinical models 
for the delivery of the anti-angiogenic compound tetraiodothyroacetic acid to tumour cells in 
the chick chorioallantoic membrane and in xenografts in mice260.
Targeted therapies and immunotherapies are proving effective for the treatment of metastatic 
renal cell carcinoma, and several approved targets (such as new immunomodulatory 
monoclonal antibodies targeting the CTLA-4 or PD-1 pathways) are already available, 
although the clinical benefits of these new therapies compared to established treatments 
(tyrosine kinase or mTOR inhibitors) remains to be shown261. Nevertheless, nanomedicine-
based approaches are of interest for the targeted delivery of chemotherapies and 
nanovaccines and their development will require further studies.
Nanotechnology has been widely applied to cancer therapy, and much has been learned 
regarding the discovery, manufacturing, and preclinical and clinical development of 
nanomedicines from several types of nonrenal cancer. We can extrapolate and infer from this 
base of knowledge to improve the design of renal carcinoma nanomedicines. Despite the fact 
that the safety profiles of most clinically validated NP platforms are superior to those of the 
parent drug, the nanomedicine does not improve survival when compared head-to-head with 
the parent drug. This absence of effect might be due, in part, to disease heterogeneity and 
variations in the degree of the enhanced permeability and retention (EPR) effect, according 
to which NPs preferentially accumulate in tumour tissues. The EPR effect has been 
suggested to have a central role in nanomedicine delivery to tumours, underscoring the need 
to select patients that are most likely to benefit from nanomedicines211,262–266. This effect 
has been widely investigated in preclinical models but few clinical studies have 
characterized it in humans or assessed its relevance to therapeutic intervention211,262–264. 
Furthermore, as understanding of the contribution of the perivascular tumour 
microenvironment to the penetration depth and uptake of NPs within tumours and into 
cancer cells has grown, we have progressively recognized that the EPR effect is complex and 
dynamic. The degree of tumour vascularization, inter-patient genetic variation, and tumour 
type and aggressiveness are all factors that contribute to this complexity211. Thus, 
stratification of patients with cancer according to tumour type and characteristics in relation 
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to the likeliness of NP accumulation might be necessary to maximize the benefits of NP-
mediated drug delivery through the EPR effect266–268.
In the past two years, preclinical efforts and preliminary clinical studies have begun to 
explore companion MRI-active nanodiagnostic molecules to dynamically assess response to 
nanomedicines265,266. Companion diagnostics could also prove valuable to assess NP 
retention, targeting, and biodistribution in the nephron using existing clinical modalities such 
as ultrasound, MRI, CT, and radiographs. These methods could be used for the assessment 
of NP accumulation within renal cell carcinomas269.
In vitro systems to assess NP efficacy
Controlled and optimized in vitro and ex vivo biological assays are required to test renal 
nanomedicines effectively. Traditional 2D cell culture models do not support complex tissue 
functions such as epithelial-to-mesenchymal transition or accurately predict the in vivo 
effects of a drug.
Microfluidics and kidney-on-a-chip
Organs-on-chips are built using microfluidic devices in which multiple cell types are 
cultured in 2D under continuous perfusion. These systems support tissue patterning in vitro 
and have been successfully used to study the molecular basis of tissue morphogenesis270. 
They also enable the screening of nanomedicines under physiological conditions270–272 
(FIG. 3). For example, exposure of epithelial monolayers of collecting duct cells and 
proximal tubule cells to an apical fluid shear stress mimicking the rate found in living kidney 
tubules in a microchip resulted in enhanced epithelial cell polarization and primary cilia 
formation and provided an environment resembling that found in vivo, which is amenable to 
toxicity studies272. In this system, fluid shear stress might have induced actin cytoskeletal 
rearrangements, resulting in a cellular phenotype akin to that found in human kidneys. A 
variety of animal and human renal cells cultured in these conditions had a toxicity response 
similar to that found in vivo. Such systems also effectively recreated epithelial-to-
mesenchymal transition, which mediates renal interstitial fibrosis272–277, and facilitated the 
measurement of P-glycoprotein ATP-binding cassette membrane (PGP, also called multidrug 
resistance protein 1 transporter activity in response to chemotherapy). Indeed, kidney tubular 
epithelial cells had more effective PGP efflux activity in baseline conditions under shear 
flow than without flow, which more closely resembles the in vivo environment than 
measures with traditional culture systems272.
Lessons from such studies could prove valuable for screening kidney-targeted drugs and 
assessing nanodrug nephrotoxicity and efficacy in a more quantitative and dynamic manner 
than traditional culture systems271,272,278.
3D culture systems
Advances in induced pluripotent stem cell technologies and in the understanding of kidney 
morphogenesis have enabled the production of mature kidney cells in vitro in 3D structures 
called organoids279–281 (FIG. 3). Organoids are self-organizing 3D tissues that can be grown 
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from embryonic stem cells, their synthetic induced pluripotent stem cells or organ-restricted 
adult stem cells282,283.
The kidney includes more than 20 specialized cell types and is an organ with complex 
structural design, which is not accurately portrayed using traditional 2D culture systems. In 
contrast, kidney organoids can be grown with more complexity, including more than 500 
nephrons and defined glomeruli with Bowman capsule and podocytes, connected to 
proximal tubules279,284.
One of the next areas of development for kidney organoids is to achieve urine and blood 
filtration in vitro, which will require a complete kidney structure with a blood system 
connected to glomerular capillary loops. Establishing patient-derived organoids is also an 
exciting avenue to develop true personalized medicines, whereby drug response can be 
predicted according to the patient’s genetic makeup. Furthermore, kidney organoids can 
facilitate testing of regenerative medicines, combination therapies, gene editing therapies 
and nanomedicine drug delivery, as they provide an environment akin to that found in the 
kidney but with the ease of manipulation of an in vivo system285. The toxicity of dendrimer 
NPs was assessed in a proximal tubule organoid, which expressed toxicity markers 
previously reported in vivo286. Such functioning proximal tubule cultures provide an 
environment similar to that found in vivo to assess the nephrotoxicity of nanomedicines and 
their cargos as they express multiple drug transporters, akin to their in vivo counterparts287.
Challenges to clinical translation
Clinical grade synthesis and screening
NPs are often composed of several components and can have a range of biophysical and 
chemical properties (size, charge, drug payload, release kinetics and surface targeting 
ligand) that require screening in a systematic and parallel fashion, while ensuring 
reproducible synthesis of libraries with such distinct features. Bulk techniques do not always 
generate uniform NPs even if they can be scaled to yield multi-kilogram batches of particles 
suitable for clinical development and commercialization288. Microfluidics have improved 
the synthesis of a variety of NP systems and enabled the controlled synthesis and high-
throughput screening of NP libraries288,289. Microfluidic technologies have the potential to 
become a platform for rapid self-assembly of NPs with a narrow size distribution, tuneable 
physical and chemical characteristics, and low batch-to-batch variability290–294. Other 
techniques such as PRINT have also been used to synthesize uniform NPs with precise 
control of size, shape, chemical composition, drug loading, and surface properties192,193. 
Analogous to high-throughput drug discovery screening, these technologies could also help 
to streamline a controlled and high-throughput investigation of kidney NP structure–activity 
relationships.
Chemistry, manufacturing and controls (CMC) and good manufacturing practice (GMP) 
requirements must continuously be met as NP technologies transition from preclinical to 
clinical development, then to commercialization and throughout the market life of the 
product. Current pharmaceutical manufacturing unit operations that generate first-generation 
NPs (liposomes and polymeric NPs) meet such demands; however, producing more complex 
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nanomedicines, such as those that incorporate targeting ligands, multidrug combinations, or 
multi-stage, stimuli-responsive, or theranostic systems, can create additional CMC requisites 
and require the adaptation of current manufacturing unit operations. The large-scale 
production of high-quality complex NPs also needs to be addressed. PRINT technology 
facilitates reproducible fabrication of NPs193, but production at the kilogram scale remains 
to be demonstrated. Alternative microfluidic technologies such as the coaxial turbulent jet 
mixer, which provides NP homogeneity, reproducibility, and tuneability, have also been 
designed and developed for large-scale production of polymeric NPs295. In the future these 
methodologies can be used to scale-up clinical-stage nanomedicines targeted to the kidney.
In vivo testing
Investigations into in vivo animal models, which can sometimes accurately mimic human 
diseases, are also important. Some studies have shown pharmacokinetics scaling across 
species (including humans) for different nanotherapeutics64,86,296,297. For instance, the AUC 
of polymeric NPs containing camptothecin (CPT) scaled linearly with CPT dose per m2 
across species (mice, rats, dogs, and humans), suggesting that NPs behave in a similar way 
in animals and in humans287. However, interspecies discrepancies exist for albumin binding 
of CPT (with higher binding affinity found for human albumin), and should be taken into 
account when considering the pharmacokinetics of the free drug in humans as this property 
might be important in investigations of NP versus free drug efficacy. Furthermore, NP 
biodistribution studies in patients are not feasible in most cases. The discrepancies between 
pre-clinical and clinical models must therefore be considered for NP development and 
animal models that more closely mimic the heterogeneity and anatomical and histological 
features of human kidney disease are needed298,299.
Conclusions and Perspectives
As the field of nanomedicine rapidly expands, with several NPs already marketed and many 
undergoing clinical trials, our accumulated experience and the clinical successes to date 
form a framework for the creation of the next generation of renal nanomedicines. Refining 
the generation of nanomaterials with tuneable biophysical properties could yield NPs with 
highly controllable architectures for kidney binding and retention as well as uptake within 
important cell types such as podocytes. Fortunately, in the past few years, numerous studies 
of NP or nano-sized colloids originally intended for tumour targeting have serendipitously 
yielded important discoveries relevant to kidney targeting and selective renal accumulation. 
These, in turn, raise important correlations between the structure and the activity of NPs 
according to their design and biophysical and chemical properties as a function of kidney 
retention and targeting. We believe that now is an ideal time for collaborative initiatives 
between nephrologists and nanotechnologists to pioneer and establish promising 
nanomedicine approaches, with appropriate selection of targeting and therapeutic parameters 
for the diagnosis and treatment of renal disease.
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Glossary
Nanoparticles
Nanoscale particles with modifiable shape and charge capable of carrying a specific payload 
(drugs, diagnostic molecules etc.).
Colloid
Substance formed by a non-crystalline material (here nanomaterial) of either natural or 
synthetic origin dispersed in a solution.
Organ-on-a-chip
Microfluidic devices used to culture living cells under continuous perfusion in micorometer-
sized chambers; they are primarily used to reproduce the physiological functions of tissues 
and organs as closely as possible.
PEGylation
Attachment of polyethers to the surface of nanoparticles in order to minimize unwanted 
interactions with their biological surroundings.
Cmax
Maximal serum concentration of a drug or nanoparticle achievable after administration.
Top-down fabrication method
Synthesis of a structure by etching or removal of material from a template or substrate to 
achieve specific shapes or sizes.
Particle replication in non-wetting templates
Fabrication technique whereby a pre-particle solution is distributed in a mould with 
nanosized cavities to generate nanoparticles with precisely defined shape, size, composition 
and surface properties.
Aspect ratio
Ratio of the width to the height of a nanoparticle.
Enhanced permeability and retention (EPR) effect
Describes the accumulation and retention of colloidal nanoparticles within tumour tissue as 
a result of increased endothelial gap junction distances due to heterogeneous vessel 
formation and growth.
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Key points
• Oncology has benefited greatly from nanotechnology research and 
investment, yielding important insights that are applicable to kidney 
nanomedicines
• Nanocarriers have the potential to improve the pharmacokinetics, 
biodistribution, toxicity, and efficacy of drugs
• Delivery and retention of nanomedicines in the kidney is challenging and 
requires a deep understanding of the renal barriers and effective engineering 
of nanoparticle size, shape, and surface chemistry
• To improve drug efficacy and minimize systemic toxicity, nanomedicines can 
be targeted to distinct kidney cell types and/or to extracellular matrix 
components such as the glomerular basement membrane
• Nanocarriers can deliver drugs, proteins, peptides and nucleic acids, and can 
facilitate the targeted delivery of genes or RNA interference molecules to treat 
kidney disorders for which the efficacy of current treatments is limited
• Organ-on-a-chip kidneys can streamline the simultaneous screening and 
testing of nanomedicines in environments that mimic the kidney and 
accelerate translation of kidney-specific therapeutics
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Figure 1. Nanoparticle composition and features
a | Nanoparticles are composed of a core (payload) encapsulated in a protective layer. The 
surface can be modified to limit the interactions of the particle with its environment. b | 
Several parameters such as size, shape and surface modification contribute to the biological 
and physicochemical properties of nanoparticles. The investigation of such properties is 
crucial to achieve the translational application of nanomedicines for kidney disease therapy. 
PEG, polyethylene glycol; ScFv Fc, single chain variable fragment constant fragment.
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Figure 2. The kidney glomerulus and the glomerular basement membrane in health and disease
The glomerular filtration barrier consists of glomerular endothelial cells, the glomerular 
basement membrane, and podocytes. All solutes and molecules with a molecular weight less 
than that of albumin (68 kDa) and a hydrodynamic diameter (HD) <5–7 nm can pass this 
barrier. The glomerular filtration barrier is negatively charged and in healthy states repels 
negatively charged proteins (such as albumin) and nanoparticles (NPs). In disease, podocyte 
effacement leads to the breakdown of the barrier and proteinuria. The presence of leaky and 
abnormal fenestrae can aid the accumulation of large and/or charged nanodrugs in the 
Bowman space.
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Figure 3. In vitro systems to test nanoparticles
a | Different types of primary renal cells can be seeded on a porous membrane coated with 
extracellular matrix (ECM) and cultured in microfluidic devices that mimic physiological 
conditions with apical fluid shear stress. These devices enable easy fluid sampling and 
addition of nanodrugs, which facilitates the high throughput testing of nanodrug 
nephrotoxicity and efficacy. b | Pluripotent stem cells can be induced to differentiatein vitro 
into mesoderm and renal organoids: 3D structures that contain several renal cell types. 
Organoids can be used as a platform to screen and test nanodrugs.
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